MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines.
MedImmune focuses on therapeutic proteins, monoclonal antibodies, and other next-generation molecules to attack a range of diseases. The company’s research organization is accountable for disease biology and target discovery, predictive sciences, safety and toxicology, early biomarker and patient stratification research, drug discovery, and pre-clinical drug development. These activities span the company’s key therapeutic areas.
MedImmune also has more than 120 research projects which aim to deliver promising new biologics to the market, playing a key role in inflammation, autoimmune and respiratory diseases, and cancer.